Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: RESTASIS

Summary for Tradename: RESTASIS

Suppliers: see list2
patent expirations by year for

Clinical Trials for: RESTASIS

A Study to Evaluate the Efficiency of Intravenously Administered Cyclosporine in de Novo Liver Transplant Recipients
Status: Completed Condition: Liver Transplantation

Gengraf Conversion Study in Stable Renal Allograft Transplant Recipients
Status: Completed Condition: End Stage Renal Failure

Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids
Status: Completed Condition: Kidney Transplantation

Study of Cyclosporine Ophthalmic Soution Group and Cyclosporine Ophthalmic Suspension Group
Status: Recruiting Condition: Dry Eye Syndromes

Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel
Status: Withdrawn Condition: Epiphora

Comparisone of Iminoral Versus Neoral in Prevention of Acute Rejection in Renal Transplantation
Status: Completed Condition: End Stage Renal Disease; Renal Transplantation

Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye
Status: Completed Condition: Dry Eye Syndromes

PK, Safety & Tolerability of CyCol® Versus Sandimmune® in Healthy Subjects
Status: Active, not recruiting Condition: Healthy

Efficacy and Safety of Basiliximab, Cyclosporine/Cyclosporine Microemulsion, and Steroids in Pediatric de Novo Liver Transplant Recipients Avoiding Intraoperative Steroids
Status: Completed Condition: Liver Transplantation; Infection

Long-term Topical Cyclosporine for Atopic Keratoconjunctivitis
Status: Completed Condition: Atopic Keratoconjunctivitis

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
EMULSION;OPHTHALMIC050790Dec 23, 2002RXYes5,474,979<disabled>Y<disabled>
EMULSION;OPHTHALMIC050790Dec 23, 2002RXYes8,629,111<disabled>Y<disabled>
EMULSION;OPHTHALMIC050790Dec 23, 2002RXYes8,633,162<disabled><disabled>
EMULSION;OPHTHALMIC050790Dec 23, 2002RXYes8,642,556<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology